Dermatite flagelada induzida por bleomicina: relato de caso / Bleomycin-induced flagellate dermatitis: a case report / Dermatitis flagelada inducida por bleomicina: relato de caso

A Dermatite Flagelada consiste de uma hiperpigmentação cutânea de aspecto flagelado, tendo como causa específica a bleomicina. A bleomicina é um agente quimioterápico usado no tratamento de diferentes neoplasias. O objetivo deste relato é descrever o caso de uma paciente de 31 anos de idade, em tratamento de Linfoma de Hodgkin com protocolo de Quimioterapia Antineoplásica composto por quatro drogas, dentre elas, a bleomicina, que cursou com o desenvolvimento da Dermatite Flagelada. Trata-se de um relato de caso ocorrido num hospital universitário do nordeste do Brasil em 2014. A terapia utilizada como tratamento foi uso de corticoide, o que proporcionou a remissão das lesões do tipo flagelo e permitiu a continuidade do tratamento sem necessidade de mudança do protocolo quimioterápico. A importância do estudo se deve por levantar discussão sobre os aspectos que envolvem o manejo dessa hipersensibilidade, para garantir a continuidade do tratamento antineoplásico (AU).

Flagellate Dermatitis consists of cutaneous hyperpigmentation with a flagellate appearance, one specific cause of which is bleomycin. Bleomycin is a chemotherapy agent used in the treatment of different neoplasias. This report's objective is to describe the case of a 31-year-old patient receiving treatment for Hodgkin Lymphoma with a protocol of Antineoplastic Chemotherapy made up of four drugs, including bleomycin, which led to the development of Flagellate Dermatitis. This is a report of a case which took place in a teaching hospital in the Northeast of Brazil in 2014. The therapy used as treatment was use of corticosteroid, which led to the remission of the lesions of the flagellate type and allow the continuation of the treatment without the need for changing the chemotherapy protocol. The study's importance lies in that it raises discussion regarding the aspects involving the management of this hypersensitivity so as to ensure the continuity of the antineoplastic treatment (AU).

La dermatitis flagelada consiste en una hiperpigmentación cutánea de aspecto flagelado y su causa específica es la bleomicina. La bleomicina es un agente quimioterápico usado en el tratamiento de diferentes neoplasias. El objetivo de este relato fue describir el caso de una paciente de 31 años de edad, en tratamiento de Linfoma de Hodgkin con protocolo de Quimioterapia Antineoplásica compuesto por cuatro drogas, entre las cuales la bleomicina, ocasionada con desarrollo de Dermatitis Flagelada. El caso ocurrió en un hospital universitario del nordeste del Brasil en 2014. La terapia utilizada como tratamiento fue uso de corticoide, lo que proporcionó la remisión de las lesiones del tipo flagelo y permitió la continuidad del tratamiento sin necesidad de cambio del protocolo quimioterápico. El papel del estudio es abrir discusión acerca de los aspectos que involucran el manejo de esa hipersensibilidad, para garantizar la continuidad del tratamiento antineoplásico (AU).

Analgesic and anti-inflammatory activities of salicylaldehyde 2-chlorobenzoyl hydrazone (H(2)LASSBio-466), salicylaldehyde 4-chlorobenzoyl hydrazone (H(2)LASSBio-1064) and their zinc(II) complexes.

Salicylaldehyde 2-chlorobenzoyl hydrazone (H(2)LASSBio-466), salicylaldehyde 4-chlorobenzoyl hydrazone (H(2)LASSBio-1064) and their complexes [Zn(LASSBio-466)H(2)O](2) (1) and [Zn(HLASSBio-1064)Cl](2) (2) were evaluated in animal models of peripheral and central nociception, and acute inflammation. All studied compounds significantly inhibited acetic acid-induced writhing response. Upon coordination the anti-nociceptive activity was favored in the complex 1. H(2)LASSBio-466 inhibited only the first phase of the formalin test, while 1 was active in the second phase, like indomethacin, indicating its ability to inhibit nociception associated with the inflammatory response. Hence coordination to zinc(II) altered the pharmacological profile of H(2)LASSBio-466. H(2)LASSBio-1064 inhibited both phases but this effect was not improved by coordination. The studied compounds did not increase the latency of response in the hot plate model, indicating their lack of central anti-nociceptive activity. All compounds showed levels of inhibition of zymosan-induced peritonitis comparable or superior to indomethacin, indicating an expressive anti-inflammatory profile.

Synthesis and pharmacological evaluation of pyrazine N-acylhydrazone derivatives designed as novel analgesic and anti-inflammatory drug candidates.

In this paper, we report the synthesis and pharmacological evaluation of pyrazine N-acylhydrazone (NAH) derivatives (2a-s) designed as novel analgesic and anti-inflammatory drug candidates. This series was planned by molecular simplification of prototype 1 (LASSBio-1018), previously described as a non-selective cyclooxygenase inhibitor. Derivatives 2a-s were evaluated in several animal models of pain and inflammation, standing-out compound 2o (2-N'-[(E)-(3,4,5-trimethoxyphenyl) methylidene]-2-pyrazinecarbohydrazide; LASSBio-1181), that was also active in a murine model of chronic inflammation (i.e., adjuvant-induced arthritis test in rats) and can be considered a new analgesic and anti-inflammatory lead for drug development.